<DOC>
	<DOC>NCT01437982</DOC>
	<brief_summary>The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%</brief_title>
	<detailed_description>The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of Lotemax ophthalmic suspension 0.5%</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Subjects who have been treated with the study drug at least once and completed safety followup. Subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment. Subjects not treated with study drug at least once.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>post-operative inflammation</keyword>
	<keyword>conjunctivitis</keyword>
	<keyword>safety</keyword>
	<keyword>Seasonal allergic conjunctivitis</keyword>
	<keyword>Giant papillary conjunctivitis</keyword>
</DOC>